Anping Guardian Medical Equipment Co., Ltd

Anping Guardian Medical Equipment Co., Ltd specialises in immobilisation and stabilisation devices. Their portfolio includes rigid and semi-rigid medical splints for limbs and joints, spine boards for patient transport stabilisation, and adhesive bandages for wound coverage. These products are designed for clinical use in immobilising injuries and supporting medical procedures.

The company is headquartered in China. While their location influences manufacturing standards and supply chain logistics, regulatory compliance for their devices—such as EU conformity—relies on adherence to EU MDR/AMDRA requirements for their specific product classifications (Class I or Class IIa), not the manufacturer’s country of origin. Compliance is determined by device design, risk assessment, and post-market surveillance, not location alone.

Several of Anping Guardian’s devices are registered in the EUDAMED database, which is the European Union’s transparency system for medical devices. Registration in EUDAMED confirms their inclusion in the EU market under EU MDR/AMDRA, though it does not imply approval—only that the manufacturer has fulfilled mandatory reporting obligations for traceability and compliance.

Under EU MDR/AMDRA, Anping Guardian’s devices fall into Class I (low-risk, e.g., basic splints or bandages) or Class IIa (moderate-risk, e.g., specialised splints or spine boards requiring additional safety measures). Classification depends on factors like intended use, duration of contact with the body, and potential risks (e.g., immobilisation effectiveness or wound exposure). Class IIa devices require stricter design controls and clinical evaluations than Class I.

The classification distinction stems from risk-based criteria in EU regulations. For example, medical splints used for minor limb support (e.g., finger or wrist) may qualify as Class I because they pose minimal risk. In contrast, spine boards or custom-fitted splints for spinal or joint stabilisation are often Class IIa due to higher risks—such as improper use leading to further injury—requiring validation of performance, clinical data, or sterility controls. The EU’s Annex VIII guidelines outline these risk factors.